2-(5-ethylthiophen-2-yl)acetic acid | 70596-08-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2-(5-ethylthiophen-2-yl)acetic acid
• 英文别名: 5-ethylthiophene-2-acetic acid；(5-ethyl-[2]thienyl)-acetic acid；(5-Aethyl-[2]thienyl)-essigsaeure
• CAS: 70596-08-6
• 化学式: C₈H₁₀O₂S
• 分子量: 170.232
• InChiKey: LHGIEVDPYLVDOI-UHFFFAOYSA-N

物化性质

• 沸点：
  287.8±25.0 °C(Predicted)
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  11
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(5-ethylthiophen-2-yl)acetic acid 在 甲酸 、 Noyori's catalyst 、 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 三氯氧磷 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 10.5h， 生成
  参考文献：
  名称：

  Design, synthesis and evaluation of benzo[a]thieno[3,2-g]quinolizines as novel l-SPD derivatives possessing dopamine D1, D2 and serotonin 5-HT1A multiple action profiles

  摘要：

  A novel scaffold derived from l-SPD with a substituted thiophene group in the D ring were designed, synthesized, and evaluated for their binding affinities at dopamine (D-1, D-2 and D-3) and serotonin (5-HT1A and 5-HT2A) receptors. Most of the tetracyclic compounds exhibited higher affinities for D-2 and 5-HT1A receptors than l-SPD, while compound 23e showed the highest K-i value of 7.54 nM at D-2 receptor which was 14 times more potent than l-SPD. Additionally, compounds 23d and 23e were more potent than l-SPD at D-3 receptor. According to the functional assays, 23d and 23e were demonstrated as full antagonists at D-1 and D-2 receptors and full agonists at 5-HT1A receptor. Since the combination of D-2 antagonism and 5-HT1A agonism is considered effective in treating both the positive and negative symptoms of schizophrenia, these novel compounds are implicated as potential therapeutic agents. (C) 2014 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2014.09.024
• 作为产物：
  描述：

  (5-ethyl-[2]thienyl)-acetonitrile 在 氢氧化钾 作用下， 生成 2-(5-ethylthiophen-2-yl)acetic acid
  参考文献：
  名称：

  Cagniant; Cagniant, Bulletin de la Societe Chimique de France, 1952, p. 713,717

  摘要：

  DOI：

文献信息

• DUAL MECHANISM INHIBITORS FOR THE TREATMENT OF DISEASE
  申请人：Aerie Pharmaceuticals, Inc.

  公开号：US20130158015A1

  公开（公告）日：2013-06-20

  Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

  提供了一些既能抑制rho激酶又能抑制单胺转运体（MAT）的化合物，这些化合物用于改善疾病状态或病情。此外，还提供了包含这些化合物的组合物。进一步提供了根据本发明给药的治疗疾病或病情的方法。其中一种疾病可能是青光眼，除了其他有益的效果外，还可以实现显著降低眼内压（IOP）的效果。
• DUAL-ACTION INHBITORS AND METHODS OF USING SAME
  申请人：deLong Mitchell A.

  公开号：US20120135984A1

  公开（公告）日：2012-05-31

  Provided are compounds, compositions, and methods for treating diseases and conditions wherein an inhibitor of a kinase, such as rho kinase (ROCK), and an inhibitor of one or more of the monoamine transporters, such as NET or SERT, act in concert to improve the condition.

  提供了化合物、组合物和方法，用于治疗疾病和情况，其中激酶抑制剂，如rho激酶（ROCK），和一种或多种单胺转运体抑制剂，如NET或SERT，共同作用以改善病情。
• The Willgerodt Reaction in the Heterocyclic Series. II. Some Compounds of the α- and β-Thienyl Series
  作者：Joseph A. Blanchette、Ellis V. Brown

  DOI：10.1021/ja01150a103

  日期：1951.6
• DIARYL[A, G]QUINOLIZIDINE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USES THEREOF
  申请人：Shanghai Institute of Materia Medica, Chinese Academy of Sciences

  公开号：EP2848617B1

  公开（公告）日：2022-01-12
• US8716310B2
  申请人：——

  公开号：US8716310B2

  公开（公告）日：2014-05-06